A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111
Status:
Active, not recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate the safety of bilateral, sequential sub-retinal
administration of a single dose of BIIB111 in adult male participants with Choroideremia
(CHM).
Phase:
Phase 2
Details
Lead Sponsor:
Nightstar Therapeutics NightstaRx Ltd, a Biogen Company